Clinical trials / NCT05453968
NCT05453968Phase 3Active not recruiting

Berotralstat Treatment in Children With Hereditary Angioedema

Study sponsor: BioCryst Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-09-11Actual
Enrollment · participants29Actual
Source updated2026-02-25Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Pharmacokinetics: Cmax Measure: Pharmacokinetics: AUC0-tau Measure: Pharmacokinetics: CL/F

+ After

Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Berotralstat Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6) of Berotralstat Measure: Concentration at the End of the Dosing Interval (Ctrough) of Berotralstat Measure: Maximum Observed Plasma Concentration (Cmax) of Berotralstat Measure: Time of Last Measurable Plasma Concentration (Tlast) of Berotralstat Measure: Time to Maximum Plasma Concentration (Tmax) of Berotralstat

Check registry source